Hostname: page-component-cd9895bd7-jn8rn Total loading time: 0 Render date: 2024-12-24T14:10:05.013Z Has data issue: false hasContentIssue false

CACN Chair’s Select Abstract Presentations

CACN 2015 President’s Prize Lidocaine for status epilepticus in pediatrics

Published online by Cambridge University Press:  03 June 2015

FA Zeiler
Affiliation:
(Winnipeg)
KJ Zeiler
Affiliation:
(Winnipeg)
J Teitelbaum
Affiliation:
(Montreal)
LM Gillman
Affiliation:
(Winnipeg)
M West
Affiliation:
(Winnipeg)
CJ Kazina
Affiliation:
(Winnipeg)
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Introduction: Our goal was to perform a systematic review of the literature on the use of intravenous lidocaine in pediatrics for status epilepticus (SE) and refractory status epilepticus (RSE) to determine its impact on seizure control. Methods: All articles from MEDLINE, BIOSIS, EMBASE, Global Health, HealthStar, Scopus, Cochrane Library, the International Clinical Trials Registry Platform (inception to November 2014), and gray literature were searched. The strength of evidence was adjudicated using both the Oxford and GRADE methodology by two independent reviewers. Results: Overall, 20 original studies were identified, with 19 manuscripts and 1 meeting abstracts. Two hundred and thirty-five pediatric patients were treated for 252 episodes of SE/RSE. Patients had varying numbers of anti-epileptic drugs (AEDs), 2 to 8, on board prior to lidocaine therapy. During 20 of the 252 (7.9%) episodes of SE/RSE, phenytoin was on board. The dose regimen of lidocaine varied, with some utilizing bolus dosing alone; others utilizing a combination of bolus and infusion therapy. Overall, 60.0% of seizures responded to lidocaine, with complete cessation and greater than 50% reduction seen in 57.6% and 12.3% respectively. Patient outcomes were sparingly reported. Conclusions: There currently exists level 2b, GRADE C evidence to support the consideration of lidocaine for SE and RSE in the pediatric population.

Type
CACN Chair’s Select Abstract Presentations
Copyright
Copyright © The Canadian Journal of Neurological Sciences Inc. 2015